NCT02720692View on ClinicalTrials.gov

Evaluation of N1539 Following Major Surgery

PHASE3CompletedINTERVENTIONAL

Enrollment

722

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

May 31, 2017

Conditions

Pain, Post-operative

Interventions

DRUG

N1539

DRUG

Intravenous Placebo

Trial Locations (32)

3121

Richmond

3206

Hamilton

4021

Kippa-Ring

4032

Chermside

4215

Southport

8024

Christchurch

16686

Tyrone

33136

Miami

33321

Tamarac

33605

Tampa

35630

Florence

35660

Sheffield

36116

Montgomery

37075

Hendersonville

43210

Columbus

44111

Cleveland

59405

Great Falls

60612

Chicago

77004

Houston

77030

Houston

78229

San Antonio

84124

Salt Lake City

85023

Phoenix

85295

Gilbert

92801

Anaheim

93301

Bakersfield

B#H2Y

Halifax

K7L2V7

Kingston

M5T2S8

Toronto

H1T2M4

Montreal

H4A3J1

Montreal

Unknown

Auckland

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Baudax Bio

INDUSTRY

NCT02720692 - Evaluation of N1539 Following Major Surgery | Biotech Hunter | Biotech Hunter